Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

Emcure Pharmaceuticals posted a 35.4 per cent year-on-year (Y-o-Y) growth in its consolidated net profit at Rs 153.7 crore ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discu ...

Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...

But now, thanks to a combination of non-profit researchers and African public-health workers, there are signs of progress ...

CFRA analysts increased their price target on shares of Sanofi (SAN:FP) (NASDAQ: NASDAQ:SNY) to EUR6.50, up from the previous EUR5.00, while keeping a Buy rating on the stock. Currently trading at $54 ...

BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics towards the end of 2023, and analysts at ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

Bioethics, a modern academic field that helps resolve such fraught dilemmas, evolved in its early decades through debates ...

In a report released today, Peter Welford from Jefferies maintained a Hold rating on AstraZeneca (AZN – Research Report), with a price target ...

The pan European Stoxx 600 climbed 0.47 per cent. The UK's FTSE 100 gained 0.61 per cent Germany's DAX ended higher by 0.37 per cent and France's CAC 40 closed down by 0.19 per cent. Switzerland's SMI ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...